Navigation Links
Oncothyreon reports full year and fourth quarter 2008 financial results
Date:3/9/2009

e Company's 2008 financial results during a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today, Monday, March 9, 2009. To listen to a webcast of the discussion, visit www.oncothyreon.com.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding future expenses, clinical development activities and the use and adequacy of cash resources.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing our product candidates, the adequacy of financing and cash reserves on hand, changes in general accounting policies, general economic factors, achievement of the results we anticipate
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
2. Oncothyreon to present at BIO CEO & Investor Conference 2009
3. Oncothyreon reports third quarter 2008 financial results
4. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
5. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
6. Oncothyreon to present at BIO Investor Forum 2008
7. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
8. Oncothyreon announces prioritization plan for development programs
9. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
10. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 For the fifth ... Inc. 500|5000 list of the fastest-growing companies. , “We’re ... acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony Pappas ... list by posting a three-year growth rate of 61 percent ... that time by more than 40 percent. , Pappas cited ...
(Date:9/23/2014)... 23, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... Q3 orders to date to $5 million. The orders are ... . "We continue to see new orders coming ... these orders, our backlog has climbed to over $11 million." ... a leading clean technology company that designs, manufactures and distributes ...
(Date:9/23/2014)... TORONTO , Sept. 23, 2014 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is pleased to announce ... (PPL) has added two more  consultants to its ... uveitis. PPL-003 uses a new proprietary cell permeable ... deliver its anti-inflammatory cargo into the eye. ...
(Date:9/23/2014)... CAMBRIDGE, Mass. , Sept. 23, 2014   ... developed a comprehensive suite of tools to enable the ... care, today announced that it has been awarded Phase ... Grant (SBIR) from the National Institutes of Health (NIH) ... biorepositories. Logo - http://photos.prnewswire.com/prnh/20140922/147649 ...
Breaking Biology Technology:ExakTime Makes Inc. 5000 List for the Fifth Time 2Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2
... ... biotechnology, ... Sciences today announced a partnership under which,Metahelix will assist in ... expert technological guidance,regarding usage. The efforts of this collaboration will ...
... Market Research, a,global provider of pharmaceutical competitive ... report providing critical strategic insight,for pharma and ... market for Rheumatoid,Arthritis (RA) therapies., In ... Analysis: Rheumatoid,Arthritis Q2 2008, MedPredict,s global Thought ...
... Arete Therapeutics Inc., a,privately-held biopharmaceutical company developing first-in-class ... of,James Sabry, M.D., Ph.D., as president and chief ... and member of the board of directors,since March ... position of,president and chief executive officer, who will ...
Cached Biology Technology:Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences 2Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences 3New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development 2Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer 2
(Date:9/23/2014)... organisms, including humans, have parasitic DNA fragments called "jumping ... instructions in the process. And that phenomenon can result ... the University of Rochester now report that the "jumping ... when a multi-function protein stops keeping them in check ... In a study published today in Nature Communications ...
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... by-products such as straw could be made quicker and ... UK and France. , Researchers funded by the ... variant straw plants whose cell walls are more easily ... significantly smaller or weaker than regular plants. , ... security as biofuels from non-food crops become easier and ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Reversing the effects of pulmonary fibrosis 2Plant variants point the way to improved biofuel production 2
... protein 'wiring' that differs markedly from the cellular circuitry ... to the development of antimalarial drugs that exploit that ... parasite responsible for an estimated 1 million deaths per ... markedly from the cellular circuitry of other higher organisms, ...
... discovery in basic plant biology that may set the stage ... scientists have identified for the first time a protein that ... toxin to kill the cell. It had been known that ... plant cells, but never before has a protein been found ...
... University have successfully cultured in a laboratory a microorganism with ... advance that may ultimately help shed light on the ecology ... smallest free living cell known and probably the most abundant ... time to study the SAR11 "proteorhodopsin" gene in a laboratory, ...
Cached Biology News:Researchers develop new method to help find deadly malaria parasite's Achilles heel 2Researchers develop new method to help find deadly malaria parasite's Achilles heel 3Biologists discover new pathway into plant cells 2Biologists discover new pathway into plant cells 3Odd energy mechanism in bacteria analyzed 2
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
Request Info...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Biology Products: